40 results about "Ige binding epitopes" patented technology

The invention relates to the field of immunity, in particular to a T cell receptor with improved affinity, a nucleic acid molecule, a carrier, a cell and a medicine containing the T cell receptor, the nucleic acid molecule, the carrier and the cell for treating tumors. The T cell receptor includes a TCR [alpha] chain variable region and a TCR [beta] chain variable region, which have activity to bind to a KRAS G12V epitope and an HLA-A * 11 complex, and the TCR [alpha] chain variable region includes CDR1 [alpha], CDR2 [alpha] and CDR3 [alpha] complementarity determining regions, and the TCR [beta] chain variable region includes CDR1 [beta], CDR2 [beta] and CDR3 [beta] complementarity determining regions. The TCR provided by the invention has high-affinity target antigen peptide binding capacity, remarkably improves the target cell recognition capacity, shows good activation and killing activity, and shows high technical value and clinical application potential.

The invention discloses lactobacillus paracasei capable of reducing casein antigenicity and application of the lactobacillus paracasei capable of reducing casein antigenicity, the strain is Lacticasei paracasei DPU-MWFLp-47 and preserved in the China General Microbiological Culture Collection Center, the preservation number is CCTCC M 20232093, the preservation number is CCTCC M 20232093, and the lactobacillus paracasei capable of reducing casein antigenicity and application of the lactobacillus paracasei capable of reducing casein antigenicity are applied to lactobacillus paracasei DPU-MWFLp-47. The strain can effectively reduce the antigenicity and potential sensitization of alpha-casein by cutting IgE binding epitopes.

The invention provides an anti-influenza A virus nano antibody and application thereof, the nano antibody comprises a heavy chain variable region, the heavy chain variable region comprises CDR1, CDR2 and CDR3, and the CDR3 of the heavy chain variable region is selected from an amino acid sequence as shown in SEQ ID NO: 8 or SEQ ID NO: 16. The anti-influenza A virus nano antibody can be combined with various influenza A viruses, including subtype influenza viruses such as H1N1, H2N2, H3N2 and H7N9, has strong broad spectrum, has different binding epitopes of the two nano antibodies, and can be applied to double antibody sandwich method detection, enzyme-linked immunosorbent assay and colloidal gold detection. According to the invention, multivalent transformation is also carried out on the nano antibody to obtain a dodecavalent hexamer cyclic structure nano antibody, so that the application scene of the anti-influenza A virus nano antibody can be further extended.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and / or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and / or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and / or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.

The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

The present invention belongs to the field of antibody technology, and specifically relates to anti-herpes zoster virus glycoprotein E monoclonal antibodies and binding epitope analysis methods. VZV gE protein is used as an immunogen to immunize mice, determine the protein titer, perform fusion experiments, and subclone experiments to obtain monoclonal antibodies. The analysis method is as follows: determine that the antibody recognition epitopes are all conformational epitopes; analyze the complete structure of the VZV gE protein, predict the disulfide bond position and antigenic epitope; mutate and identify the cysteine ​​residues in the VZV gE sequence predicted to form disulfide bonds or affect the formation of disulfide bonds one by one; transfect and express the recombinant mutant plasmid, detect the expression of mutant and wild-type proteins; detect the activity of monoclonal antibodies; detect the activity of monoclonal antibodies corresponding to the mutant proteins with the same expression amount; and detect the affinity of monoclonal antibodies. Application: pharmaceutical composition, reagent, test strip or kit, biological product. The present invention fills the gap in the current analysis of conformational epitopes of VZV gE protein antigens.

Disclosed is an activator of regulatory T cells, an inhibitor of activity of effector T cells, an inhibitor of activation of B cells, an inhibitor of humoral immunity, or a therapeutic or prophylactic agent for an autoimmune disease, containing a polypeptide including an amino acid sequence equivalent to an HLA-DR binding epitope of an AChR.

The present disclosure is directed recombinant T cell receptors capable of binding a MUC5AC epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

The present disclosure relates to recombinant T cell receptors capable of binding to NY-ESO-1 epitopes and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the present disclosure relate to vectors comprising the nucleic acid molecules and cells comprising the recombinant TCRs, the nucleic acid molecules, or the vectors. Other aspects of the present disclosure relate to methods of using the recombinant TCRs, the nucleic acid molecules, the vectors, and the cells. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

The present application relates to the technical field of antibodies, in particular to a monoclonal antibody specifically targeting human SLC46A2 and application thereof. The present application expresses and purifies human SLC46A2 protein through a eukaryotic expression system; then uses the purified human SLC46A2 protein as an immunogen to immunize mice to produce antibodies; finally, a monoclonal antibody AB144 specifically recognizing and binding to human SLC46A2 protein is obtained through flow enrichment and screening, and the epitope recognized and bound by the antibody is identified; the complex structure of human SLC46A2-Fab144 is analyzed through cryo-EM to further determine the binding epitope of the antibody. It has been verified that the monoclonal antibody AB144 provided by the present application can specifically recognize and bind to the amino acid residues of human SLC46A2 protein, has high affinity, and can be used as a molecular tool for the detection of human SLC46A2 protein.

The present invention relates to the field of immunology, and particularly to a T cell receptor with enhanced affinity, a nucleic acid molecule, a vector, a cell, and a medicament for treating tumors comprising them. The T cell receptor comprises a variable region of the TCR α chain and a variable region of the TCR β chain, which has the activity of binding to the KRAS G12V epitope and the HLA-A*11 complex, and the variable region of the TCR α chain comprises CDR1α, CDR2α, and CDR3α complementarity-determining regions, and the variable region of the TCR β chain comprises CDR1β, CDR2β, and CDR3β complementarity-determining regions. The TCR provided by the present invention has the ability to bind to the target antigen peptide with high affinity, significantly improves the target cell recognition ability, and at the same time exhibits good activation and killing activities, showing strong technical value and clinical application potential.

The present disclosure is directed to recombinant T cell receptors (and fragments thereof) capable of binding a HPV16 E6 epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

Some embodiments of the systems and methods provided herein relate to an assay. Some such embodiments include multiplex affinity probes and an antigen probe. multiplex affinity probes and an antigen probe Some embodiments include contacting a biological sample with the probes, wherein target binding agents such as antibodies in the biological sample compete away the multiplex affinity probes from binding to the antigen probe. Some such embodiments include detecting a decrease in binding of the multiplex affinity probes to the antigen probe, thereby indicating the presence or an amount of the target binding agents in the biological sample.

The invention discloses a neutralizing antibody targeting a filovirus host receptor NPC1 and an antibody fusion protein of a broad-spectrum neutralized filovirus and a mutant thereof, the neutralizing antibody is composed of a specific heavy chain and a specific light chain, can specifically bind to an NPC1-C structural domain of the host receptor NPC1 protein, has a clear binding epitope, still has binding activity in an endosome acidic environment, and can be used for preparing a recombinant filovirus. The light chain of the antibody fusion protein constructed on the basis of the neutralizing antibody contains NPC2 protein and flexible Linker, the antibody fusion protein has broad-spectrum neutralizing activity on high-pathogenicity filoviruses and mutant strains thereof, and a new thought and a new strategy are provided for research and development of anti-filovirus infection drugs; good application prospects and industrial conversion values are realized.

The invention belongs to the field of biological medicine, and particularly relates to a CD3 specific binding protein, a bispecific antibody and a preparation method and application of the bispecific antibody. The invention provides a bispecific antibody. The bispecific antibody comprises a first antigen binding domain specifically binding to CD3 and a second antigen binding domain specifically binding to AMHR2 or GPC3. Wherein a CD3 antibody single-chain variable fragment (ScFV) in the first antigen binding domain can be combined with T cells, the second antigen binding domain is combined with antigens on the tumor surface, and the combination mode can obviously activate the functions of the T cells. Compared with a CD3 terminal antibody in a traditional T cell bispecific antibody, the T cell bispecific antibody has different binding epitopes, can maintain high tumor cell killing activity and also has a low cytokine release level, so that the effectiveness and safety of T cell bispecific antibody treatment can be balanced.

The present disclosure provides an antibody or an antigen-binding fragment thereof, wherein the antibody or the antigen-binding fragment thereof specifically binds to TSLP. The antibody of the present invention can effectively inhibit the activation of TSLP on the STATs and JAK2 signaling pathways of H_TSLP Reporter Cell Line cells, and the antibody of the present invention and Tezepelumab can effectively inhibit the proliferation-promoting effect of TSLP on BaF3-TSLPR / IL7Rα cells. The antibody of the present invention does not cross the binding epitope of Tezepelumab, and will not block the MKK34 antimicrobial peptide with antibacterial activity at the C-terminus, and is expected to retain the ability of TSLP to resist external bacterial infection.

The present disclosure relates to recombinant T cell receptors capable of binding to the gp100 epitope and nucleic acid molecules encoding the recombinant T cell receptors. In some embodiments, the nucleic acid molecule further comprises a second nucleotide sequence, wherein the second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of endogenous TCR. Other aspects of the present disclosure relate to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule or the vector. Other aspects of the present disclosure relate to methods of using the recombinant TCR, the nucleic acid molecule, the vector and the cell. In some embodiments, the method comprises treating cancer in a subject in need thereof.

The present disclosure relates to recombinant T cell receptors capable of binding to NY-ESO-1 epitopes and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the present disclosure relate to vectors comprising the nucleic acid molecules and cells comprising the recombinant TCRs, the nucleic acid molecules, or the vectors. Other aspects of the present disclosure relate to methods of using the recombinant TCRs, the nucleic acid molecules, the vectors, and the cells. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

The present invention discloses a rat anti-mouse CD137 antibody or its functional fragment, a tool antibody and its application, which relates to the field of biotechnology. This antibody has high specificity, high affinity, and the binding epitope of the antibody to the mouse CD137 molecule is clear, and it can be used for the detection of mouse CD137 molecule. In particular, the rat anti-mouse CD137 antibody provided by the present invention has excellent T cell activation effect and shows good in vivo tumor inhibition effect. Accordingly, the rat anti-mouse CD137 antibody provided by the present invention is not only of great significance for the development and research of CD137 monoclonal antibodies and bispecific antibodies, but also provides a unique research tool for exploring the mechanism of action of specific types of CD137 antibodies in mouse tumor models and new combinations of combination therapies based on CD137 antibodies, potentially guiding the research and development of a new generation of CD137 antibody drugs.

The present disclosure is directed recombinant T cell receptors capable of binding a CCND1 epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

The present invention belongs to the field of biomedicine technology and relates to the application of a β-lactoglobulin-specific aptamer. Based on the co-localization phenomenon between the binding epitope of a β-lactoglobulin cyclic aptamer on the surface of β-lactoglobulin and the binding epitope of the antibody IgE on the surface of β-lactoglobulin, the present invention can effectively mask the allergen binding epitope on the surface of β-lactoglobulin. The invention proposes the use of a β-lactoglobulin-specific aptamer to alleviate cow's milk allergic reactions caused by β-lactoglobulin. Cell experiments and animal experiments have verified that the cyclic aptamer can effectively inhibit allergic reactions caused by β-lactoglobulin, and has good application prospects in alleviating cow's milk allergic reactions.

This disclosure relates to a recombinant T-cell receptor capable of binding to the gp100 epitope and a nucleic acid molecule encoding said recombinant T-cell receptor. In some embodiments, the nucleic acid molecule further comprises a second nucleotide sequence, wherein said second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of endogenous TCRs. Other aspects of this disclosure relate to a vector comprising said nucleic acid molecule and a cell comprising said recombinant TCR, said nucleic acid molecule, or said vector. Other aspects of this disclosure relate to methods of using said recombinant TCR, said nucleic acid molecule, said vector, and said cell. In some embodiments, said methods include treating a subject with cancer in need.

The present disclosure provides an antibody or an antigen-binding fragment thereof, wherein the antibody or the antigen-binding fragment thereof specifically binds to TSLP. The antibody of the present application can effectively inhibit the activation of TSLP on the STATs and JAK2 signaling pathway of H_TSLP Reporter Cell Line cells, and both the antibody of the present application and Tezepelumab can effectively inhibit the proliferation promoting effect of TSLP on BaF3-TSLPR / IL7Rα cells. The antibody of the present application does not cross the binding epitope of Tezepelumab, does not block the antibacterial peptide MKK34 with antibacterial activity at the C-terminus, and is expected to retain the ability of TSLP to resist bacterial infection from the outside.

The present disclosure relates to recombinant T cell receptors capable of binding to NY-ESO-1 epitopes and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the present disclosure relate to vectors comprising the nucleic acid molecules and cells comprising the recombinant TCRs, the nucleic acid molecules, or the vectors. Other aspects of the present disclosure relate to methods of using the recombinant TCRs, the nucleic acid molecules, the vectors, and the cells. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

The present invention provides a polypeptide having the formula: St-R1-S1-Q-S2-R2 wherein St is a stalk sequence which, when the polypeptide is expressed at the surface of a target cell, causes the R and Q epitopes to be projected from the cell surface; R1 and R2 are a Rituximab-binding epitopes each having the an amino acid sequence selected from the group consisting of SEQ ID No. 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 or a variant thereof which retains Rituximab-binding activity, S1 and S2 are optional spacer sequences, which may be the same or different; and Q is a QBEnd10-binding epitope having the amino acid sequence shown as SEQ ID No. 2 or a variant thereof which QBEnd10-binding activity. The invention also provides a nucleic acid sequence encoding such a polypeptide and uses thereof in adoptive cell transfer.

Anti-CD33 antibodies are described. The anti-CD33 antibodies can bind within the V-set Ig-like domain or the C2-set Ig-like domain of CD33. Epitopes on the C2-set Ig-like domain can provide a “pan-binding” site, to which the cognate antibody will bind regardless of whether the CD33 molecule also contains the V-set domain (as in, for example, CD33FL) or not (as in, for example, CD33ΔE2). Alternative epitopes on the C2-set Ig-like domain are accessible for binding if the V-set domain is absent (e.g., as in CD33ΔE2). Antibodies that bind an epitope on the C2-set Ig-like domain (whether they exhibit pan or V-set absent binding) are directed at novel therapeutic targets and can increase therapeutic efficacy against CD33-related disorders. Also described are molecules comprising a binding-competent domain from at least one described anti-CD33 antibody, including scFvs, bi-specific antibody molecules, chimeric antigen receptors, and immunoconjugates. Methods of use are also provided.

The present disclosure relates to recombinant T cell receptors capable of binding to a MUC5AC epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the present disclosure relate to vectors comprising the nucleic acid molecules and cells comprising the recombinant TCRs, the nucleic acid molecules, or the vectors. Other aspects of the present disclosure relate to methods of using the recombinant TCRs, the nucleic acid molecules, the vectors, and the cells. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

Disclosed is an activator for regulatory T cells, an inhibitor of the activity of effector T cells, an inhibitor of the activation of B cells, an agent for suppressing humoral immunity, or a therapeutic agent or a prophylactic agent for an autoimmune disease, which contains a polypeptide comprising an amino acid sequence corresponding to an HLA-DR-binding epitope of an AChR.